AMHR2 Polymorphism in Blood and Granulosa Cells in Unexplained Infertility

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

96 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are various known parameters for assessing ovarian reserve, including ovarian volume, antral follicle count, follicle stimulating hormone (FSH) and Inhibin B at the beginning of the menstrual cycle, as well as anti-Mullerian hormone (AMH). Anti-müllerian hormone is a dimeric glycoprotein and a member of the transforming growth factor β family that plays a role in the regulation of follicular development. AMH is produced by granulosa cells of the early developing follicles in the ovary, and continues to be expressed in the growing follicles until these follicles have reached a size of 4-6 mm and a differentiation state at which AMH becomes receptive for exogenous FSH, and may be selected for dominance.It exerts its biological effects through the receptor AMHR2, which is present on granulosa and theca cells. Considering the important role of the AMH signalling pathway in regulating FSH sensitivity in the ovary and follicular recruitment and selection, it is appropriate to consider that variation in the genes encoding key proteins in the pathway may influence ovarian response. The aim of this study is to investigate the effect of the distribution of single gene polymorphisms of the AMHR2 receptor gene A-482G/rs200255 in patients with unexplained infertility and to compare this distribution with the distribution in women without infertility.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins

NCT02237781

Female Infertility

UNKNOWN PHASE2/PHASE3

AMH and Pregnancy Outcome in IVF

NCT04512807

AMH

UNKNOWN

Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients

NCT02293668

Infertility

COMPLETED NA

Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old

NCT01219387

AMH Levels Inhibin B Levels IVF Patients Over 38 Years Old

COMPLETED

Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program

NCT02640976

Infertility

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective, controlled cohort study was conducted at IVF Centre of Department of Obstetrics and Gynecology, Bezmialem University Hospital between October 2022 and April 2023. The study protocol was approved by the Ethical Committee of the Medical Faculty of Bezmialem University. Written informed consent was obtained from all patients. This trial was designed and reported according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines.

The patients were divided into 3 groups. Group 1 (study group; unexplained infertilitiy, n=32), Group 2 ( first control group; healthy women with a history of at least one successful previous pregnancy, n=32), Group 3 ( second control group; infertile patients undergo IVF because of male or tubal factor, n=32). Inclusion criteria for the study were as follows: \<40 years of age, normal serum levels of TSH and prolactin presence of both ovaries without any morphological abnormalities, normal ovulatory cycles (25-35 days), body mass index (BMI) ≤30, no previous history of poor response and no evidence of endocrine disease, such as polycystic ovary syndrome, hipo-hyper prolactinemia, no use of hormone therapy in the 6 months preceding the recruitment and commencing IVF treatment. Patients with moderate/severe endometriosis (stage III and IV), previous ovarian surgery or underwent chemo/radiotherapy excluded from the study.

At the first application, peripheral blood will be taken from the Study group, 1st Control and 2nd Control group to evaluate polymorphisms of the AMHR2-482A\>G(rs200255) with PCR analysis. During IVF treatment at the day of ovum pick up; follicular fluid will be collected to isolate granulosa cell for polymorphisms of the AMHR2-482A\>G(rs200255) with PCR analysis.

The total number of embryos, the number of embryos transferred, the number of frozen and viable embryos will be recorded. After the embryo transfer is performed in the study group and the 2nd control group, the pregnancy results will be recorded by checking the bhcg in the blood on the 10-12th day of the transfer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility, Female AMH IVF

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group

Patients with Unexplained İnfertility

AMHR2 polymorphism in blood

Intervention Type GENETIC

1 tube of blood taken at the first application

AMHR2 polymorphism in granulosa cell

Intervention Type GENETIC

Extraction of granulosa cell from the follicle fluid obtained during OPU

First Control Group

Healthy Multiparous Women

AMHR2 polymorphism in blood

Intervention Type GENETIC

1 tube of blood taken at the first application

Second Control Group

A: Patients with male infertility B: Patients with tubal factor

AMHR2 polymorphism in blood

Intervention Type GENETIC

1 tube of blood taken at the first application

AMHR2 polymorphism in granulosa cell

Intervention Type GENETIC

Extraction of granulosa cell from the follicle fluid obtained during OPU

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMHR2 polymorphism in blood

1 tube of blood taken at the first application

Intervention Type GENETIC

AMHR2 polymorphism in granulosa cell

Extraction of granulosa cell from the follicle fluid obtained during OPU

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* unexplained infertility (study group)
* a healthy women with a history of at least one successful previous pregnancy resulting from spontaneous conception (first control group)
* infertility caused by male factor, tubal factor (second control group)
* \<40 years of age
* normal serum levels of TSH and prolactin
* presence of both ovaries without any morphological abnormalities
* normal ovulatory cycles (25-35 days)
* body mass index (BMI) ≤30
* no previous history of poor response and no evidence of endocrine disease, such as polycystic ovary syndrome, hipo-hyper prolactinemia
* no use of hormone therapy in the 6 months preceding the recruitment
* undergoing IVF